Participating Companies


Axial Biotherapeutics, Inc.
The com­pany's bio­ther­a­peu­tics prod­ucts har­ness the gut-brain axis to de­vel­op nov­el Cen­tral Ner­vous Sys­tem (CNS) Ther­a­peu­tics to im­prove the qual­i­ty of life for peo­ple with CNS dis­eas­es and di­s­or­ders, pro­vid­ing med­i­cal pro­fes­sio­n­als and health­care in­sti­tu­tions with a new ap­proach for di­ag­nos­ing and treat­ing PD and ASD and po­ten­tial­ly other CNS dis­eas­es. [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr2,491 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
Bioarctic AB [BIOA.B:ST] SKr7,930 MM MCap
In the Parkin­son’s Dis­ease area, BioArc­tic has a part­n­er­ship with Ab­b­vie to de­vel­op AB­BV-0805 and other an­ti-al­pha synu­clein anti­bodies. In ad­di­tion, BioArc­tic is de­vel­op­ing a blood brain bar­ri­er tran­s­port tech­nol­o­gy plat­form and imag­ing and bio­chem­i­cal bio­mark­ers for Alzheimer’s and Parkin­son’s dis­eas­es in vari­ous col­lab­o­ra­tions. [more in­for­ma­tion]
Boundless Bio
De­vel­op­er of nov­el can­cer ther­a­peu­tics in­tend­ed to un­der­s­tand and treat in­trace­able can­cers. The com­pany is in the pro­cess of de­vel­op­ing a nov­el class of can­cer drugs and ex­trachro­mo­so­mal DNA (ecD­NA) that elim­i­nates can­cer cells abil­i­ty to em­ploy ecD­NA to sur­vive, en­abling health­care pro­fes­sio­n­als to treat most-dif­fi­cult can­cers. [more in­for­ma­tion]
Candesant Biomedical
Can­de­sant Biomed­i­cal is de­vel­op­ing a com­pelling prod­uct to un­lock the po­ten­tial of the sweat con­trol mar­ket. Fur­ther, the prod­uct will pro­vide a great val­ue to the con­sumer with an eco­nom­ic in­cen­tive to the treat­ing physi­cians. [more in­for­ma­tion]
Caribou Biosciences
Cari­bou is a lead­ing com­pany in CRIS­PR genome edit­ing found­ed by pi­oneers of CRIS­PR bi­ol­o­gy. The com­pany is de­vel­op­ing an in­ter­nal pipe­line of off-the-shelf CAR-T cell ther­a­pies, other gene-edit­ed na­t­u­ral killer (NK) cell ther­a­pies, and en­gi­neered gut mi­crobes. In­ves­tors in­clude: An­ter­ra Cap­i­tal; Mis­sion Bay Cap­i­tal; No­var­tis [more in­for­ma­tion]
Cernostics, Inc.
De­vel­op­er of tis­sue-based di­ag­nos­tic test de­signed to quan­ti­fy the com­plex­i­ty of the tis­sue sys­tem. The com­pany's di­ag­nos­tic test unique­ly an­a­lyzes whole slide dig­i­tal im­ages with mul­ti­plexed flu­o­res­cence, pro­vid­ing physi­cians and pa­tients with in­di­vi­d­u­al­ized, ac­tion­able in­for­ma­tion to im­prove out­comes and re­duce the in­ci­dence and mor­tal­i­ty of can­cer. [more in­for­ma­tion]
CerSci Therapeutics
De­vel­op­ing a new gen­er­a­tion of non-opi­oid medicines to treat acute post-op­er­a­tive and chron­ic neu­ro­path­ic pain. Lead pro­gram in Phase 1 (MAD/SAD/Food Ef­fect), CT-044, tar­get­ing re­ac­tive spe­cies that cause neu­ro­n­al ion chan­nel hy­per-sen­si­ti­za­tion, known to trig­ger pain. [more in­for­ma­tion]
Crescendo Biologics
Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic for PS­MA-pos­i­tive tu­mours. Cres­cen­do’s pipe­line of T cell en­hanc­ing molecules is un­der­pinned by its nov­el, pa­tent-pro­tect­ed Hum­a­body® plat­form, which gen­er­ates ful­ly hu­man VH do­mains. [more in­for­ma­tion]
Dynacure
Dy­nacure is a clin­i­cal-stage drug de­vel­op­ment com­pany fo­cused on im­prov­ing the lives of pa­tients with rare and or­phan dis­eas­es. The Dy­nacure team lev­er­ages its proven track re­cord in rare dis­ease drug de­vel­op­ment to build a pipe­line of nov­el drugs. [more in­for­ma­tion]
Exicure [XCUR] US$152 MM MCap
Cavro­toli­mod (AST-008) in Ph2 trials for pa­tients with Merkel Cell Car­ci­no­ma and Cu­ta­neous Squa­mous Cell Car­ci­no­ma, with Ph1b da­ta pre­sent­ed at AACR 2020. XCUR-FXN in pre­clin­i­cal de­vel­op­ment for pa­tients with Frie­dreich's Ataxia, us­ing ge­net­i­cal­ly tar­get­ed SNA ther­a­pies to re­move FXN tran­scrip­tion block­age, with IND ex­pect­ed in late 2020. [more in­for­ma­tion]
Faraday Pharmaceuticals
El­e­men­tal re­duc­ing agents for crit­i­cal care treat­ment to pre­vent car­di­ac and skele­tal mus­cle loss: lead can­di­date FDY-5301 Ph 3 (piv­o­tal) to ini­ti­ate mid-2020 for reper­fu­sion in­jury fol­low­ing heart at­tack (AMI); da­ta ear­ly 2023. SPA sub­mis­sion re­ceived by FDA Jan 22, 2020 and ini­tial feed­back re­ceived Feb 2020 - Type A meet­ing re­quest, like­ly in April 2020. Sig­ni­f­i­cant ad­di­tio­n­al treat­ment ap­pli­ca­tions with limit­ed to no com­pe­ti­tion. $57M raised to date from Arch Ven­ture Part­n­ers, Po­laris Part­n­ers, WRF, Osa [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €115 MM MCap
Hei­del­berg Phar­ma AG (WL6, Frank­furt Stock Exchange), based in La­den­burg, Ger­many, is a lead­ing biotech com­pany pi­oneer­ing the use of its AT­AC (Anti­body Tar­get­ed Amanitin Con­ju­gate) plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion ef­fec­tive at spe­cif­i­cal­ly killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mour re­sis­tance mech­anisms. [more in­for­ma­tion]
HiFiBiO
The com­pany's drug of­fers ul­tra-high-through­put anti­body se­lec­tion, un­prece­dent­ed sin­gle-cell re­s­o­lu­tion and in­te­grates deep-root­ed bi­o­log­i­cal ex­per­tise with com­pre­hen­sive pro­fil­ing tech­nolo­gies, en­abling doc­tors to iden­ti­fy ther­a­peu­tic molecules for the treat­ment of can­cer and au­toim­mune di­s­or­ders. [more in­for­ma­tion]
Incysus Therapeutics
The com­pany's ser­vices fo­cus on uti­l­iz­ing ge­net­i­cal­ly mod­i­fied gam­ma-del­ta T cells across a Drug Re­sis­tance Im­munother­a­py (DRI) plat­form that ad­dress­es the chal­lenges faced while tar­get­ing cold, low mu­ta­tion can­cers, en­abling the tar­get­ing of ma­lig­nant cells and po­ten­tial­ly more ef­fec­tive treat­ments for pa­tients with dif­fi­cult-to-treat solid tu­mor can­cers. [more in­for­ma­tion]
Inventiva Pharma [IVA:PA] €378 MM MCap
The com­pany is fo­cused on de­vel­op­ing its prod­uct can­di­date, lan­i­fi­branor, for the treat­ment of pa­tients with non-al­co­holic stea­to­he­p­ati­tis, or NASH, a dis­ease for which there are cur­rent­ly no ap­proved ther­a­pies. The com­pany is al­so in­volved in de­vel­op­ing a port­fo­lio of pre-clin­i­cal ther­a­py pro­grams. [more in­for­ma­tion]
ISA Pharmaceuticals BV
is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]
Landos Biopharma
Based on ex­ten­sive pre­clin­i­cal studies, Lan­dos has vali­dat­ed a unique mech­anism of ac­tion in­volv­ing LAN­CL2 that ex­erts po­tent an­ti-in­flam­ma­to­ry ef­fects with an out­s­tand­ing safe­ty pro­file. Lead as­set BT-11 Phase 2 in­ter­im read out in mid-2020 in UC. [more in­for­ma­tion]
NervGen Pharma [NGENF] US$36 MM MCap
Nerv­Gen Phar­ma is a de­vel­op­ing nov­el ther­a­peu­tics for pa­tients suf­fer­ing from med­i­cal con­di­tions re­lat­ed to nerve da­m­age sus­tained as a re­sult of (i) in­jury, such as in spi­nal cord in­jury, or (ii) neu­rode­gen­er­a­tive dis­ease, such as MS or Alzheimer's dis­ease. [more in­for­ma­tion]
PCI Biotech AS [PCIB:OS] NKr1,874 MM MCap
fi­maCHEM which is an en­hance­ment of che­mother­a­peu­tics for lo­cal­ized treat­ment of can­cer, fi­ma­VACC which is T-cell in­duc­tion tech­nol­o­gy for ther­a­peu­tic vac­ci­na­tion, and fi­maNAc which is nu­cle­ic acid ther­a­peu­tics de­liv­ery. The op­er­at­ing seg­ment of the group is Re­search and de­vel­op­ment. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Signed li­cens­ing agree­ment with Jazz Phar­ma for Lur­binecte­din in the US - up­front pay­ment of $200M, $100mm on ap­pro­va­land up to $550M sales mile­s­tones. Jazz to launch Zepzel­ca in US Ju­ly 2020. [more in­for­ma­tion]
Secarna Pharmaceuticals GmbH
Se­car­na's unique­ly ef­fi­cient LNA­plus™ dis­cov­ery pro­cess is fu­eled by their pro­pri­e­tary and stream­lined Oli­go­fy­er™ bioin­for­mat­ics sys­tems large in-house cell li­brary and own in vit­ro screen­ing as­says. [more in­for­ma­tion]
Sensorion [ALSEN:PA] €129 MM MCap
Sen­so­ri­on is a clin­i­cal-stage biotech and gene ther­a­py com­pany that spe­cial­izes in the de­vel­op­ment of nov­el ther­a­pies to re­s­tore, treat and pre­vent within the field of hear­ing loss di­s­or­ders. SENS-401 is in a Phase 2 clin­i­cal trial as a treat­ment for sud­den sen­sorineu­ral hear­ing loss. [more in­for­ma­tion]
Vaccinex, Inc. [VCNX] US$36 MM MCap
Its lead prod­uct, pepinemab, is an anti­body against semaphorin 4D, a nov­el im­munother­a­py tar­get to mo­d­u­late im­mune re­sponse to solid tu­mors and chron­ic in­flam­ma­tion that drives neu­rode­gen­er­a­tive dis­eas­es. [more in­for­ma­tion]
Zentalis [ZNTL] US$1,337 MM MCap
In ad­di­tion to its lead pro­gram, ZN-c5, an oral SERD for es­tro­gen re­cep­tor pos­i­tive, HER2-neg­a­tive breast can­cer, the Com­pany is de­vel­op­ing a broad pipe­line of on­col­o­gy can­di­dates, tar­get­ing ar­eas of ma­jor un­met med­i­cal need. [more in­for­ma­tion]